Pharmacology of commonly used analgesics and sedatives in the ICU: Benzodiazepines, propofol, and opioids

Anesthesiology Clinics

Volumn 29, Issue 4, 2011, Pages 567-585

  Devlin, John W ^a,b   Roberts, Russel J ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Analgesia; Critical care; Fentanyl; Lorazepam; Midazolam; Opioids; Propofol; Sedation

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FENTANYL; HYDROMORPHONE; LORAZEPAM; METHADONE; MIDAZOLAM; MORPHINE; OPIATE DERIVATIVE; PETHIDINE; PROPOFOL; PROPYLENE GLYCOL; SEDATIVE AGENT;

ACUTE KIDNEY FAILURE; AGITATION; AMNESIA; ANALGESIA; BRADYCARDIA; BRONCHOSPASM; CONSTIPATION; DEATH; DELIRIUM; DISORIENTATION; DRUG COST; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EUPHORIA; FLUSHING; HALLUCINATION; HEART ARREST; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; ILEUS; INTENSIVE CARE; INTENSIVE CARE UNIT; METABOLIC ACIDOSIS; MUSCLE RIGIDITY; NAUSEA; PHARMACODYNAMICS; PHARMACOGENETICS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; URTICARIA; VOMITING;

EID: 81055150471     PISSN: 19322275     EISSN: 22103538     Source Type: Journal    
DOI: 10.1016/j.anclin.2011.09.001     Document Type: Review

References (99)

1. Sessler C.N., Varney K. Patient-focused sedation and analgesia in the ICU. Chest 2008, 133(2):552-565.
2. Jacobi J., Fraser G.L., Coursin D.B., et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002, 30(1):119-141.
3. Payen J.F., Chanques G., Mantz J., et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007, 106(4):687-695. [quiz: 891-2].
4. Weinert C.R., Calvin A.D. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. Crit Care Med 2007, 35(2):393-401.
5. Puntillo K.A. Pain experiences of intensive care unit patients. Heart Lung 1990, 19(5 Pt 1):526-533.
6. Kress J.P., Pohlman A.S., O'Connor M.F., et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000, 342(20):1471-1477.
7. Devlin J.W., Tanios M.A., Epstein S.K. Intensive care unit sedation: waking up clinicians to the gap between research and practice. Crit Care Med 2006, 34(2):556-557.
8. Brook A.D., Ahrens T.S., Schaiff R., et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999, 27(12):2609-2615.
9. Pandharipande P.P., Pun B.T., Herr D.L., et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007, 298(22):2644-2653.
10. Mehta S., Burry L., Fischer S., et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006, 34(2):374-380.
11. Martin J., Franck M., Sigel S., et al. Changes in sedation management in German intensive care units between 2002 and 2006: a national follow-up survey. Crit Care 2007, 11(6):R124.
12. Riker R.R., Fraser G.L. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 2005, 25(5 Pt 2):8S-18S.
13. Wagner B.K., O'Hara D.A. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet 1997, 33(6):426-453.
14. Devlin J.W., Barletta J.F. Chapter 21: principles of drug dosing in critically ill patients. Critical care medicine: principles of diagnosis and management in the adult 2008, 343-376. Mosby Elsevier, Philadelphia. 3rd edition. J.E. Parrillo, R.P. Dellinger (Eds.).
15. Power B.M., Forbes A.M., van Heerden P.V., et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998, 34(1):25-56.
16. Bodenham A., Shelly M.P., Park G.R. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988, 14(6):347-373.
17. Spina S.P., Ensom M.H. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007, 27(3):389-398.
18. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003, 348(6):529-537.
19. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007, 81(3):429-444.
20. Lotsch J., Skarke C., Liefhold J., et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004, 43(14):983-1013.
21. Smith H.S. Variations in opioid responsiveness. Pain Physician 2008, 11(2):237-248.
22. Fredheim O.M., Moksnes K., Borchgrevink P.C., et al. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008, 52(7):879-889.
23. Trescot A.M., Datta S., Lee M., et al. Opioid pharmacology. Pain Physician 2008, 11(2 Suppl):S133-S153.
24. Armstrong P.J., Bersten A. Normeperidine toxicity. Anesth Analg 1986, 65(5):536-538.
25. Mao J., Price D.D., Lu J., et al. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats. Neurosci Lett 1998, 250(3):193-196.
26. Pergolizzi J., Boger R.H., Budd K., et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8(4):287-313.
27. Hall L.G., Oyen L.J., Murray M.J. Analgesic agents. Pharmacology and application in critical care. Crit Care Clin 2001, 17(4):899-923. viii.
28. Barr J., Donner A. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin 1995, 11(4):827-847.
29. Lugo R.A., MacLaren R., Cash J., et al. Enteral methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU. Pharmacotherapy 2001, 21(12):1566-1573.
30. Toombs J.D., Kral L.A. Methadone treatment for pain states. Am Fam Physician 2005, 71(7):1353-1358.
31. Davies G., Kingswood C., Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996, 31(6):410-422.
32. Gutstein H.B., Akil H. Opioid analgesics. Goodman and Gilman's the pharmacologic basis of therapeutics 2006, 547-590. McGraw-Hill, New York. 11th edition. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
33. Walder B., Tramer M.R. Analgesia and sedation in critically ill patients. Swiss Med Wkly 2004, 134(23-24):333-346.
34. Dahaba A.A., Grabner T., Rehak P.H., et al. Remifentanil versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. Anesthesiology 2004, 101(3):640-646.
35. Muellejans B., Lopez A., Cross M.H., et al. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]. Crit Care 2004, 8(1):R1-R11.
36. Karabinis A., Mandragos K., Stergiopoulos S., et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Crit Care 2004, 8(4):R268-R280.
37. Breen D., Karabinis A., Malbrain M., et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial [ISRCTN47583497]. Crit Care 2005, 9(3):R200-R210.
38. Patanwala A.E., Duby J., Waters D., et al. Opioid conversions in acute care. Ann Pharmacother 2007, 41(2):255-266.
39. Dumas E.O., Pollack G.M. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J 2008, 10:537-551.
40. Tobias J.D. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med 2000, 28(6):2122-2132.
41. Hofbauer R., Tesinsky P., Hammerschmidt V., et al. No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit. Eur J Anaesthesiol 1999, 16(10):702-707.
42. Meyer M.M., Berens R.J. Efficacy of an enteral 10-day methadone wean to prevent opioid withdrawal in fentanyl-tolerant pediatric intensive care unit patients. Pediatr Crit Care Med 2001, 2(4):329-333.
43. Eap C.B., Broly F., Mino A., et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001, 21(2):229-234.
44. Crettol S., Deglon J.J., Besson J., et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005, 78(6):593-604.
45. Eap C.B., Crettol S., Rougier J.S., et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007, 81(5):719-728.
46. Darbari D.S., van Schaik R.H., Capparelli E.V., et al. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008, 83(3):200-202.
47. Benyamin R., Trescot A.M., Datta S., et al. Opioid complications and side effects. Pain Physician 2008, 11(2 Suppl):S105-S120.
48. Gaudreau J.D., Gagnon P., Roy M.A., et al. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 2007, 109(11):2365-2373.
49. Moryl N., Kogan M., Comfort C., et al. Methadone in the treatment of pain and terminal delirum in advanced cancer patients. Palliat Support Care 2005, 3(4):311-317.
50. Benitez-Rosario M.A., Feria M., Salinas-Martin A., et al. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 2004, 101(12):2866-2873.
51. Mirski M.A., Hemstreet M.K. Critical care sedation for neuroscience patients. J Neurol Sci 2007, 261(1-2):16-34.
52. Thomas J., Karver S., Cooney G.A., et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008, 358(22):2332-2343.
53. Amrein R., Hetzel W., Hartmann D., et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl 1988, 2:65-80.
54. Ghoneim M.M., Mewaldt S.P. Benzodiazepines and human memory: a review. Anesthesiology 1990, 72(5):926-938.
55. Masica A.L., Girard T.D., Wilkinson G.R., et al. Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients. Am J Geriatr Pharmacother 2007, 5(3):218-231.
56. McKenzie C.A., McKinnon W., Naughton D.P., et al. Differentiating midazolam over-sedation from neurological damage in the intensive care unit. Crit Care 2005, 9(1):R32-R36.
57. Shelly M.P., Mendel L., Park G.R. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987, 42(6):619-626.
58. Bauer T.M., Ritz R., Haberthur C., et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995, 346(8968):145-147.
59. Swart E.L., van Schijndel R.J., van Loenen A.C., et al. Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med 1999, 27(8):1461-1465.
60. Barr J., Zomorodi K., Bertaccini E.J., et al. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology 2001, 95(2):286-298.
61. Swart E.L., Zuideveld K.P., de Jongh J., et al. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur J Clin Pharmacol 2006, 62(3):185-194.
62. Kollef M.H., Levy N.T., Ahrens T.S., et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998, 114(2):541-548.
63. Pandharipande P., Shintani A., Peterson J., et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006, 104(1):21-26.
64. Devlin J.W., Fong J.J., Fraser G.L., et al. Delirium assessment in the critically ill. Intensive Care Med 2007, 33(6):929-940.
65. Schelling G., Stoll C., Haller M., et al. Health-related quality of life and posttraumatic stress disorder in survivors of the acute respiratory distress syndrome. Crit Care Med 1998, 26(4):651-659.
66. Girard T.D., Shintani A.K., Jackson J.C., et al. Risk factors for post-traumatic stress disorder symptoms following critical illness requiring mechanical ventilation: a prospective cohort study. Crit Care 2007, 11(1):R28.
67. Shelly M.P., Sultan M.A., Bodenham A., et al. Midazolam infusions in critically ill patients. Eur J Anaesthesiol 1991, 8(1):21-27.
68. Cigada M., Pezzi A., Di Mauro P., et al. Sedation in the critically ill ventilated patient: possible role of enteral drugs. Intensive Care Med 2005, 31(3):482-486.
69. Fukasawa T., Suzuki A., Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007, 32(4):333-341.
70. Haas C.E., Kaufman D.C., Jones C.E., et al. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003, 31(5):1338-1346.
71. Barnes B.J., Gerst C., Smith J.R., et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy 2006, 26(1):23-33.
72. Nelsen J.L., Haas C.E., Habtemariam B., et al. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med 2008, 23(3):184-194.
73. Yahwak J.A., Riker R.R., Fraser G.L., et al. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy 2008, 28(8):984-991.
74. Parker M.G., Fraser G.L., Watson D.M., et al. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med 2002, 28(1):81-84.
75. McKeage K., Perry C.M. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003, 17(4):235-272.
76. Marik P.E., Varon J. The management of status epilepticus. Chest 2004, 126(2):582-591.
77. Kelly D.F., Goodale D.B., Williams J., et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. J Neurosurg 1999, 90(6):1042-1052.
78. Ravussin P., Guinard J.P., Ralley F., et al. Effect of propofol on cerebrospinal fluid pressure and cerebral perfusion pressure in patients undergoing craniotomy. Anaesthesia 1988, 43 Suppl:37-41.
79. Bailie G.R., Cockshott I.D., Douglas E.J., et al. Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 1992, 68(5):486-491.
80. Peeters M.Y., Bras L.J., DeJongh J., et al. Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther 2008, 83(3):443-451.
81. Barr J., Egan T.D., Sandoval N.F., et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology 2001, 95(2):324-333.
82. Carson S.S., Kress J.P., Rodgers J.E., et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006, 34(5):1326-1332.
83. de Wit M., Best A.M., Epstein S.K., et al. Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. Int J Clin Pharmacol Ther 2006, 44(10):466-473.
84. Girard T.D., Kress J.P., Fuchs B.D., et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008, 371(9607):126-134.
85. Devlin J.W., Lau A.K., Tanios M.A. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 2005, 25(10):1348-1352.
86. Huettemann E., Jung A., Vogelsang H., et al. Effects of propofol vs methohexital on neutrophil function and immune status in critically ill patients. J Anesth 2006, 20(2):86-91.
87. Fodale V., La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 2008, 31(4):293-303.
88. Bray R.J. Fatal myocardial failure associated with a propofol infusion in a child. Anaesthesia 1995, 50(1):94.
89. Bray R.J. Propofol infusion syndrome in children. Paediatr Anaesth 1998, 8(6):491-499.
90. Fudickar A., Bein B., Tonner P.H. Propofol infusion syndrome in anaesthesia and intensive care medicine. Curr Opin Anaesthesiol 2006, 19(4):404-410.
91. Vasile B., Rasulo F., Candiani A., et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003, 29(9):1417-1425.
92. Baumeister F.A., Oberhoffer R., Liebhaber G.M., et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics 2004, 35(4):250-252.
93. Wolf A., Weir P., Segar P., et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001, 357(9256):606-607.
94. Diprivan for I.V. administration vol. 2007.
95. Fong J.J., Sylvia L., Ruthazer R., et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med 2008, 36(8):2281-2287.
96. Ostermann M.E., Keenan S.P., Seiferling R.A., et al. Sedation in the intensive care unit: a systematic review. JAMA 2000, 283(11):1451-1459.
97. Ferrari A., Coccia C.P., Bertolini A., et al. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004, 50(6):551-559.
98. Charney D.S., Mihic S.J., Harris R.A. Hypnotics and sedatives. Goodman and Gilman's the pharmacological basis of therapeutics 2006, 401-429. McGraw-Hill, New York. 11th edition. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
99. MacLaren R., Sullivan P.W. Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients. Pharmacotherapy 2005, 25(10):1319-1328.